REFERENCES
- Daniel D G, Whitcomb S R. Treatment of the refractory schizophrenic patient. Journal of Clinical Psychiatry 1998; 59: 13–19, (Suppl. 1)
- Morrison D P. Management of treatment refractory schizophrenia. British Journal of Psychiatry 1996; 169: 15–20, (Suppl. 31)
- Aitchison K J, Kerwin R W. Cost-effectiveness of clozapine: a UK clinic-based study. British Journal of Psychiatry 1997; 171: 125–130
- Herman M. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital. Australian and New Zealand Journal of Mental Health Nursing 1997; 337: 809–815
- Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997; 337: 809–815
- Essock S M, Hargreaves W A, Covell N H, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomised trial. Psychopharmacology Bulletin 1996; 32: 683–697
- Grace J, Bellus S B, Raulin M L, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services 1996; 47: 41–45
- Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. British Journal of Psychiatry 1995; 167: 760–764
- Meltzer H Y, Cola P A. The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry 1994; 55: 161–165, (9, Suppl. B)
- Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990; 41: 882–885
- Frankenburg F R, Zanarini M C, Cole J O, McElroy S L. Hospitalization rates among clozapine-treated patients: a prospective cost benefit analysis. Annals of Clinical Psychiatry 1992; 4: 247–250
- Terkelsen K G, Grosser R C. Estimating clozapine's cost to the nation. Hospital and Community Psychiatry 1990; 41: 863–869
- Rosenheck R, Charney D S, Frisman L K, Cramer J. Clozapine's cost-effectiveness [letter]. American Journal of Psychiatry 1995; 152: 152–153
- Breier A, Buchanan R W, Irish D, Carpenter W T. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hospital and Community Psychiatry 1993; 44: 1145–1149
- Drew L RH, Hodgson Clozapine D. Community use in the Australian Capital Territory. Australian Journal of Psychopharmacology 1997; 8: 46
- Overall J E, Gorham D R. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 799–812
- Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic V R. The side-effects of clozapine: a four year follow-up study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994; 18: 537–534
- Hargreaves W A, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry 1996; 57: 66–76, (Suppl. 9)
- Schiller M, Hargreaves W A. Clozapine's costs effectiveness [letter]. American Journal of Psychiatry 1995; 152: 151–152
- Rosenheck R, Massari L, Frisman L. Who should receive high-cost mental health treatment and for how long?. Schizophrenia Bulletin 1993; 19: 843–852
- Schooler N R. New antipsychotic medications: strategies for evaluation and selected findings. Schizophrenia Research 1997; 27: 249–259